Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy

Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 11 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Varlitinib (Primary) ; Capecitabine
  • Indications Adenocarcinoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TreeTopp
  • Sponsors ASLAN Pharmaceuticals
  • Most Recent Events

    • 11 Nov 2019 Topline results presented in the ASLAN Pharmaceuticals media release.
    • 11 Nov 2019 Primary endpoint (Progression-free survival (PFS) - part 1) has not been met, according to a ASLAN Pharmaceuticals media release.
    • 11 Nov 2019 Primary endpoint (Objective response rate (ORR) - part 1) has not been met, according to a ASLAN Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top